$OMAB

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. (NASDAQ:OMAB) Given Average Recommendation of "Hold" by Brokerages

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. (NASDAQ:OMAB) has received an average "Hold" recommendation from six brokerages, with an average one-year target price of $106. The company recently missed quarterly earnings and revenue estimates, reporting EPS of $1.40 versus $1.65 expected and revenue of $228.23M against $241.63M, although it maintains strong net margins and return on equity. The stock opened at $110.61 with a market cap of $4.71 billion and trades below its 50-day simple moving average.

Original reporting
MarketBeat · MarketBeat
Published Mar 12, 2026, 6:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 12, 2026, 7:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Grupo Aeroportuario del Centro Norte S.A.B. de C.V. (NASDAQ:OMAB) Given Average Recommendation of "Hold" by Brokerages — source image
Decision brief

The 30-second read

$OMABNeutralLow
01

Why it matters

The earnings miss and neutral analyst consensus suggest cautious investor sentiment, but fundamental strengths remain. Technical indicators point to potential near-term weakness, yet long-term prospects are supported by sector fundamentals.

02

Market read

Limited immediate trading impact; primarily relevant for regional transportation sector investors and long-term shareholders.

03

What to watch

Potential upcoming catalysts such as infrastructure investments or sector reforms could improve outlook; macroeconomic factors affecting regional travel demand should also be considered.

Relevance 6/10Timing: medium-term (next 1-3 months)

Background

Grupo Aeroportuario del Centro Norte operates regional airports in Mexico, serving a key transportation corridor with steady passenger growth historically.

Company-level read

Ticker impact

$OMABNeutralMedium confidence
Context

Primary focus of the news, relevant for airport infrastructure and regional transportation sectors.

Expected impact

Potential short-term decline or sideways movement; limited upside expected in the near term.

Evidence & confidence

Earnings miss and below-average analyst rating suggest caution, but strong fundamentals and sector position mitigate downside risk.

Market effects

Potentially negative impact on transportation and infrastructure sectors; regional airports may face similar sentiment shifts.

Limited, primarily affecting regional markets in Mexico and nearby regions.

Low, as the company is focused on regional operations and the news is company-specific.

Counterpoint

The earnings miss may be a short-term anomaly; long-term investors could view the strong margins and ROE as signs of resilience, making the stock a potential value opportunity at current levels.

Key entities

  • Grupo Aeroportuario del Centro Norte

    Regional airport operator in Mexico.

Related articles

$EDMed

What iShares Global Infra ETF (IGF) Bought: Con Ed Leads on Sept

iShares Global Infrastructure ETF (IGF) reported $17.6M in net buying on Sept 30, including a new $112.5M stake in Consolidated Edison (ED). Other notable buys were Grupo Aeroportuario del Pacifico (PAC) and Grupo Aeroportuario del Centro Norte (OMAB). IGF also sold out of PG&E (PCG) and trimmed positions in Cheniere Energy (LNG) and Williams (WMB).

$OMABMedAI 9/10

8 Best Airport Stocks to Buy According to Hedge Funds

Research and Markets valued the global airport operations market at $96.3B in 2024, projecting 4.06% CAGR to $125.8B by 2031. UISEE Technologies said it aims for fully autonomous airports by the next decade; its Hong Kong IPO raised $111M. The article lists airport stocks favored by hedge funds, including OMAB and ASR, citing recent traffic and earnings updates.

$JHigh

Jacobs unit wins $1B San Francisco wastewater upgrade contract (J:NYSE)

Jacobs (J) secured a $1B contract from the San Francisco Public Utilities Commission for a nutrient reduction project at the Southeast Treatment Plant, aiming to protect San Francisco Bay. The project will enhance wastewater treatment infrastructure. According to Jacobs, this reflects their expertise in environmental solutions. The contract is expected to boost the company's revenue and backlog.

$MLYSHighAI 9/10

Mineralys Therapeutics, Inc. (MLYS) Phase 2 CKD Trial Meets BP Endpoint

Mineralys Therapeutics reported that its Phase 2 Explore-CKD trial met the primary endpoint, with lorundrostat 25 mg reducing systolic blood pressure by 7.5 mmHg vs. placebo at 4 weeks. The treatment also showed reductions in UACR and urine protein, along with a drop in serum aldosterone. The company aims for further trials to confirm sustained benefits and FDA review.

$MLYSMedAI 9/10

Adding a medicine lowered the top blood pressure reading by 7.5 mmHg vs placebo in a kidney trial

Mineralys Therapeutics (MLYS) reported that its Phase 2 Explore-CKD trial met its primary endpoint, showing a 7.5 mmHg reduction in systolic blood pressure for lorundrostat 25 mg once daily vs. placebo at four weeks. The trial involved 59 participants with uncontrolled hypertension, CKD, and albuminuria. Lorundrostat also reduced urinary protein loss and serum aldosterone levels. The company plans further evaluation of the drug's potential benefits for these conditions.